Author

Stephen B Hanauer 1

1 Feinberg School of Medicine,Chicago,United States

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF OZANIMOD, AN ORAL S1P RECEPTOR MODULATOR, IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF THE MAINTENANCE PERIOD OF THE TOUCHSTONE STUDY

William Sandborn, Brian G. Feagan, Douglas C. Wolf, Geert R. D'Haens, Severine Vermeire, Stephen B Hanauer, Subrata Ghosh, Heather Smith, Matt Cravets, Paul A. Frohna, Richard Aranda, Sheila Gujrathi, Allan Olson

ADALILMUMAB SERUM CONCENTRATION AS A PREDICTOR FOR CLINICAL EFFICACY - ROC ANALYSES

Nael M. Mostafa, Anne M. Robinson, Shringi Sharma, William Sandborn, Subrata Ghosh, Stephen B Hanauer, Roopal B Thakkar, Walid Awni

ADJUNCTIVE ALLOPURINOL IN THIOPURINE NON-RESPONDERS OPTIMISES 6TGN AND IMPROVES CLINICAL OUTCOMES IN IBD: THE MULTICENTRE, PROSPECTIVE, DOUBLE BLIND, DOSE-RANGING AAA STUDY

Antony B. Friedman, Steven J. Brown, Peter A. Bampton, Murray Barclay, Alvin Chung, Finlay A. Macrae, John V. Reynolds, Peter R. Gibson, Stephen B Hanauer, Miles P. Sparrow

Clinical Remission Demonstrated with Oral Ozanimod in the Overall Population and Across Multiple Subgroups of Patients with Moderately to Severely Active Ulcerative Colitis in the TOUCHSTONE Trial

Brian G. Feagan, William Sandborn, Geert R. D'Haens, Steve Hanauer, Douglas C. Wolf, Severine Vermeire, Subrata Ghosh, Annkatrin Petersen Jappelli, Steven Ye Hua, Kevin Shan, W Jerry Liu

EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE: RESULTS FROM IM-UNITI LONG-TERM EXTENSION THROUGH 3 YEARS

William Sandborn, Paul Rutgeerts, Douglas Jacobstein, Christopher Gasink, Rishit Patel, Bin Zou, Jewel Johanns, Bruce E. Sands, Stephen B Hanauer, Stephan Targan, Subrata Ghosh, Willem de Villiers, Jean-Frederic Colombel, Brian G. Feagan

EFFICACY OF USTEKINUMAB FOR INDUCTION AND MAINTENANCE OF ENDOSCOPIC HEALING IN PATIENTS WITH CROHN?S DISEASE

Paul Rutgeerts, Christopher Gasink, Daphne Chan, Yinghua Lang, Paul Pollack, Stephen B Hanauer, Douglas C. Wolf, Douglas Jacobstein, Jewel Johanns, Philippe Szapary, Brian G. Feagan, William Sandborn

EXPOSURE-EFFICACY RELATIONSHIP (ER) FOR ADALIMUMAB DURING INDUCTION PHASE OF TREATMENT OF ADULT PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (UC)

Nael M. Mostafa, Doerthe Eckert, Rajendra S Pradhan, Sven Mensing, Anne M. Robinson, Stephen B Hanauer, Jean-Frederic Colombel, Roopal B Thakkar, Walid Awni, William Sandborn

High versus standard adalimumab induction dosing regimens in patients with moderately to severely active Crohn's disease: Results from the SERENE-CD induction study

Geert D‘Haens, William Sandborn, Edward Loftus, Steve Hanauer, Stefan Schreiber, Laurent Peyrin-Biroulet, Remo Panaccione, Julian Panés, Jean-Frédéric Colombel, Marc Ferrante, Edouard Louis, Alessandro Armuzzi, Qian Zhou, Bidan Huang, Nisha V. Kwatra, Nael M. Mostafa, Thao Doan, Joel Petersson, Alex Song, Anne M. Robinso

Identification of risk factors associated with loss of response to ustekinumab in Crohn's disease

Steve Hanauer, Bruce E. Sands, Brian G. Feagan, A Oortwijn, Roger van Kruchten, Victor Laliman, James Izanec, Joseph Adedokun, Long-Long Gao, Sheldon Sloan, Christopher Gasink, S Targan, Willem de Villiers, Paul Rutgeerts, Jean-Frédéric Colombel, Subrata Ghosh

INTER-OBSERVER AGREEMENT IN BOWEL ULTRASONOGRAPHY FOR DIAGNOSTIC ASSESSMENT IN PATIENTS WITH CROHN?S DISEASE 

Emma Calabrese, Torsten Kucharzik, Christian Maaser, Giovanni Maconi, Deike Strobel, Stephanie R. Wilson, Francesca Zorzi, Kerri L. Novak, David H. Bruining, Marietta Iacucci, Mamoru Watanabe, Elisabetta Lolli, Carlo Chiaramonte, Stephen B Hanauer, Remo Panaccione, Francesco Pallone, Giovanni Monteleone, Subrata Ghosh

Item 1 - 10 / 29
1
2 3